Novo Nordisk limits starter doses of Wegovy due to high demand surpassing supply. Current patients unaffected, but new patients may face difficulties until September. Increased demand for weight-loss drugs leads to supply shortages. FDA-approved Wegovy and sister drug Ozempic gain popularity. Prescription filling issues anticipated, past supply problems highlighted. Wegovy shortage worsened by production problems. Celebrity endorsements bring attention to semaglutide and Wegovy. Promotion of Wegovy paused to manage demand. Dosages and side effects of Wegovy explained. Novo Nordisk working to address supply problems.